Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Substantial reduction in losses
Demand normalisation post the second wave contributed to the steady growth
Anti-malaria API facility will be operational in 15-18 months
It plays a pivotal role in monitoring pharmaceutical pricing
A treatment to prevent extreme symptoms and cut hospitalisation
Subscribe To Our Newsletter & Stay Updated
